[{"address1": "5980 Horton Street", "address2": "Suite 600", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 250 7800", "website": "https://www.omniab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.", "fullTimeEmployees": 95, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew W. Foehr", "age": 50, "title": "President, CEO & Director", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 967716, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kurt A. Gustafson", "age": 55, "title": "Executive VP of Finance & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 558477, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles S. Berkman J.D.", "age": 54, "title": "Chief Legal Officer & Secretary", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 734327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cia  McCaffrey", "title": "Vice President of People & Talent", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bill  Harriman Ph.D.", "title": "Senior Vice President of Antibody Discovery", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marie-Cecile  van de Lavoir D.V.M., Ph.D.", "title": "Senior Vice President of Technical Operations & Genetics", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christel  Iffland Ph.D.", "title": "Senior Vice President of Antibody Technologies", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas S. Krafte Ph.D.", "age": 65, "title": "Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head", "yearBorn": 1958, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Donna  Ventura CPA", "title": "Senior Vice President of Corporate Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.6, "open": 5.63, "dayLow": 5.415, "dayHigh": 5.69, "regularMarketPreviousClose": 5.6, "regularMarketOpen": 5.63, "regularMarketDayLow": 5.415, "regularMarketDayHigh": 5.69, "forwardPE": -11.122448, "volume": 446446, "regularMarketVolume": 446446, "averageVolume": 513916, "averageVolume10days": 569070, "averageDailyVolume10Day": 569070, "bid": 5.36, "ask": 5.7, "bidSize": 900, "askSize": 1000, "marketCap": 633840448, "fiftyTwoWeekLow": 3.14, "fiftyTwoWeekHigh": 6.715, "priceToSalesTrailing12Months": 9.798575, "fiftyDayAverage": 5.9276, "twoHundredDayAverage": 5.23095, "currency": "USD", "enterpriseValue": 563046144, "profitMargins": -0.45985, "floatShares": 94716686, "sharesOutstanding": 116301000, "sharesShort": 5078027, "sharesShortPriorMonth": 4885219, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0437, "heldPercentInsiders": 0.04457, "heldPercentInstitutions": 0.75097, "shortRatio": 14.53, "shortPercentOfFloat": 0.047399998, "impliedSharesOutstanding": 116301000, "bookValue": 2.792, "priceToBook": 1.9520056, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -29746000, "trailingEps": -0.26, "forwardEps": -0.49, "enterpriseToRevenue": 8.704, "enterpriseToEbitda": -27.927, "52WeekChange": 0.68674695, "SandP52WeekChange": 0.33757293, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OABI", "underlyingSymbol": "OABI", "shortName": "OmniAb, Inc.", "longName": "OmniAb, Inc.", "firstTradeDateEpochUtc": 1633008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d14c9ca6-0744-365b-9ae8-349bf02bcf56", "messageBoardId": "finmb_1765536061", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.45, "targetHighPrice": 11.0, "targetLowPrice": 7.0, "targetMeanPrice": 9.63, "targetMedianPrice": 10.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 96628000, "totalCashPerShare": 0.831, "ebitda": -20161000, "totalDebt": 26176000, "quickRatio": 4.101, "currentRatio": 4.264, "totalRevenue": 64687000, "debtToEquity": 8.065, "revenuePerShare": 0.66, "returnOnAssets": -0.0708, "returnOnEquity": -0.106759995, "freeCashflow": 16199000, "operatingCashflow": 4325000, "revenueGrowth": -0.207, "grossMargins": 1.0, "ebitdaMargins": -0.31167, "operatingMargins": -3.70623, "financialCurrency": "USD", "trailingPegRatio": null}]